Immunic AG – Home

Immunic AG is a young biotech company based in the Munich biotech hub Martinsried that develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in its pathogenesis.


Mission of Immunic AG: Immunic AG is a start-up biotech company focused on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The final aim is to develop these drug candidates to clinical proof of concept.

Immunic will attend Bio-Europe, which will take place November 6-8, 2017 in Berlin, Germany.

The 23rd annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. This year over 3,800 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe. It ...
Read More

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

  Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing Series A financing round now completed with an overall ...
Read More

Immunic Adds EUR 4 Million in Funding to Further Boost Development

Series A financing round extended to EUR 21.7 Million Immunic’s investor base broadened by IBG fund which is managed by bmp Beteiligungsmanagement Expanded funding accelerates further development of IMU-838 and ...
Read More